These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1101 related items for PubMed ID: 26261492

  • 1. Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells.
    Lyu H, Huang J, Edgerton SM, Thor AD, He Z, Liu B.
    Int J Clin Exp Pathol; 2015; 8(6):6143-56. PubMed ID: 26261492
    [Abstract] [Full Text] [Related]

  • 2. Functional interaction between mouse erbB3 and wild-type rat c-neu in transgenic mouse mammary tumor cells.
    Kim A, Liu B, Ordonez-Ercan D, Alvarez KM, Jones LD, McKimmey C, Edgerton SM, Yang X, Thor AD.
    Breast Cancer Res; 2005; 7(5):R708-18. PubMed ID: 16168116
    [Abstract] [Full Text] [Related]

  • 3. Functional cooperation of miR-125a, miR-125b, and miR-205 in entinostat-induced downregulation of erbB2/erbB3 and apoptosis in breast cancer cells.
    Wang S, Huang J, Lyu H, Lee CK, Tan J, Wang J, Liu B.
    Cell Death Dis; 2013 Mar 21; 4(3):e556. PubMed ID: 23519125
    [Abstract] [Full Text] [Related]

  • 4. The anti-erbB3 antibody MM-121/SAR256212 in combination with trastuzumab exerts potent antitumor activity against trastuzumab-resistant breast cancer cells.
    Huang J, Wang S, Lyu H, Cai B, Yang X, Wang J, Liu B.
    Mol Cancer; 2013 Nov 11; 12(1):134. PubMed ID: 24215614
    [Abstract] [Full Text] [Related]

  • 5. Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer.
    Wang S, Huang J, Lyu H, Cai B, Yang X, Li F, Tan J, Edgerton SM, Thor AD, Lee CK, Liu B.
    Breast Cancer Res; 2013 Nov 11; 15(5):R101. PubMed ID: 24168763
    [Abstract] [Full Text] [Related]

  • 6. HDAC inhibitor SNDX-275 enhances efficacy of trastuzumab in erbB2-overexpressing breast cancer cells and exhibits potential to overcome trastuzumab resistance.
    Huang X, Wang S, Lee CK, Yang X, Liu B.
    Cancer Lett; 2011 Aug 01; 307(1):72-79. PubMed ID: 21497990
    [Abstract] [Full Text] [Related]

  • 7. The erbB3- and IGF-1 receptor-initiated signaling pathways exhibit distinct effects on lapatinib sensitivity against trastuzumab-resistant breast cancer cells.
    Lyu H, Yang XH, Edgerton SM, Thor AD, Wu X, He Z, Liu B.
    Oncotarget; 2016 Jan 19; 7(3):2921-35. PubMed ID: 26621843
    [Abstract] [Full Text] [Related]

  • 8. Loss of Nrdp1 enhances ErbB2/ErbB3-dependent breast tumor cell growth.
    Yen L, Cao Z, Wu X, Ingalla ER, Baron C, Young LJ, Gregg JP, Cardiff RD, Borowsky AD, Sweeney C, Carraway KL.
    Cancer Res; 2006 Dec 01; 66(23):11279-86. PubMed ID: 17145873
    [Abstract] [Full Text] [Related]

  • 9. Computational modeling of ERBB2-amplified breast cancer identifies combined ErbB2/3 blockade as superior to the combination of MEK and AKT inhibitors.
    Kirouac DC, Du JY, Lahdenranta J, Overland R, Yarar D, Paragas V, Pace E, McDonagh CF, Nielsen UB, Onsum MD.
    Sci Signal; 2013 Aug 13; 6(288):ra68. PubMed ID: 23943608
    [Abstract] [Full Text] [Related]

  • 10. Estrogenic promotion of ErbB2 tyrosine kinase activity in mammary tumor cells requires activation of ErbB3 signaling.
    Liu B, Ordonez-Ercan D, Fan Z, Huang X, Edgerton SM, Yang X, Thor AD.
    Mol Cancer Res; 2009 Nov 13; 7(11):1882-92. PubMed ID: 19861407
    [Abstract] [Full Text] [Related]

  • 11. AKT3 regulates ErbB2, ErbB3 and estrogen receptor α expression and contributes to endocrine therapy resistance of ErbB2(+) breast tumor cells from Balb-neuT mice.
    Grabinski N, Möllmann K, Milde-Langosch K, Müller V, Schumacher U, Brandt B, Pantel K, Jücker M.
    Cell Signal; 2014 May 13; 26(5):1021-9. PubMed ID: 24463007
    [Abstract] [Full Text] [Related]

  • 12. Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells.
    Hutcheson IR, Knowlden JM, Hiscox SE, Barrow D, Gee JM, Robertson JF, Ellis IO, Nicholson RI.
    Breast Cancer Res; 2007 May 13; 9(4):R50. PubMed ID: 17686159
    [Abstract] [Full Text] [Related]

  • 13. Heregulin negatively regulates transcription of ErbB2/3 receptors via an AKT-mediated pathway.
    Awasthi S, Hamburger AW.
    J Cell Physiol; 2014 Nov 13; 229(11):1831-41. PubMed ID: 24692179
    [Abstract] [Full Text] [Related]

  • 14. Downregulation of erbB3 abrogates erbB2-mediated tamoxifen resistance in breast cancer cells.
    Liu B, Ordonez-Ercan D, Fan Z, Edgerton SM, Yang X, Thor AD.
    Int J Cancer; 2007 May 01; 120(9):1874-82. PubMed ID: 17266042
    [Abstract] [Full Text] [Related]

  • 15. Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b.
    Scott GK, Goga A, Bhaumik D, Berger CE, Sullivan CS, Benz CC.
    J Biol Chem; 2007 Jan 12; 282(2):1479-86. PubMed ID: 17110380
    [Abstract] [Full Text] [Related]

  • 16. EGF receptor inhibitors increase ErbB3 mRNA and protein levels in breast cancer cells.
    Grøvdal LM, Kim J, Holst MR, Knudsen SL, Grandal MV, van Deurs B.
    Cell Signal; 2012 Jan 12; 24(1):296-301. PubMed ID: 21951604
    [Abstract] [Full Text] [Related]

  • 17. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation.
    Holbro T, Beerli RR, Maurer F, Koziczak M, Barbas CF, Hynes NE.
    Proc Natl Acad Sci U S A; 2003 Jul 22; 100(15):8933-8. PubMed ID: 12853564
    [Abstract] [Full Text] [Related]

  • 18. Novel anti-ErbB3 monoclonal antibodies show therapeutic efficacy in xenografted and spontaneous mouse tumors.
    Aurisicchio L, Marra E, Luberto L, Carlomosti F, De Vitis C, Noto A, Gunes Z, Roscilli G, Mesiti G, Mancini R, Alimandi M, Ciliberto G.
    J Cell Physiol; 2012 Oct 22; 227(10):3381-8. PubMed ID: 22213458
    [Abstract] [Full Text] [Related]

  • 19. Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin.
    Wang S, Huang X, Lee CK, Liu B.
    Oncogene; 2010 Jul 22; 29(29):4225-36. PubMed ID: 20498641
    [Abstract] [Full Text] [Related]

  • 20. Hypoxia/HIF1α induces lapatinib resistance in ERBB2-positive breast cancer cells via regulation of DUSP2.
    Karakashev SV, Reginato MJ.
    Oncotarget; 2015 Feb 10; 6(4):1967-80. PubMed ID: 25596742
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 56.